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Aims The prognosis of patients hospitalized for worsening heart failure (HF) is well described, but not that of patients
managed solely in non-acute settings such as primary care or secondary outpatient care. We assessed the distribution
of HF across levels of healthcare, and assessed the prognostic differences for patients with HF either recorded in
primary care (including secondary outpatient care) (PC), hospital admissions alone, or known in both contexts.
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Methods
and results
This study was part of the CALIBER programme, which comprises linked data from primary care, hospital admissions,
and death certificates for 2.1million inhabitants of England. We identified 89 554 patients with newly recorded HF, of
whom 23 547 (26%) were recorded in PC but never hospitalized, 30 629 (34%) in hospital admissions but not known
in PC, 23 681 (27%) in both, and 11 697 (13%) in death certificates only. The highest prescription rates of ACE
inhibitors, beta-blockers, and mineralocorticoid receptor antagonists was found in patients known in both contexts.
The respective 5-year survival in the first three groups was 43.9% [95% confidence interval (CI) 43.2–44.6%], 21.7%
(95% CI 21.1–22.2%), and 39.8% (95% CI 39.2–40.5%), compared with 88.1% (95% CI 87.9–88.3%) in the age- and
sex-matched general population.
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Conclusion In the general population, one in four patients with HF will not be hospitalized for worsening HF within a median
follow-up of 1.7 years, yet they still have a poor 5-year prognosis. Patients admitted to hospital with worsening HF
but not known with HF in primary care have the worst prognosis and management. Mitigating the prognostic burden
of HF requires greater consistency across primary and secondary care in the identification, profiling, and treatment
of patients.
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Introduction
Management of chronic diseases with acute exacerbations, such
as heart failure (HF), is often fragmented across primary and
secondary care.1–4 Yet, most clinical trials and registries that
have guided HF care and informed patients about their prognosis
have had a HF-related hospitalization as a prerequisite for study
enrolment. As a result, the extent to which this evidence should be
extrapolated to HF patients seen in other levels of the healthcare
system, those who are never hospitalized for example, remains
largely uninvestigated. Therefore, as for many diseases, external
validity of HF trials and cohorts is questionable and reflects
the paucity in our understanding of how evidence should be
generalized into guidelines.5
The challenge to prognosticate heterogeneous diseases such
as HF was recently reinforced by data from the Swedish health-
care system, showing that patients included in trials were poorly
representative of patients with HF encountered in the general
population, and approximately one in three such patients had
never been hospitalized for HF.6 Data from Sweden and other
population-based studies from various countries are now increas-
ingly available.6–8 However, to date, most studies that report on
prognosis of HF produced survival estimates for HF in general,9–14
acute hospital admissions,15–19 or stratified for cardiac systolic
dysfunction20–24 (i.e. reduced-, mid-, or preserved range of LVEF)
for example. We hypothesize that prognostication of HF can merit
from strata based on level of care to allow assessment of novel
patient groups, such as patients known with HF in ambulatory care
(i.e. primary or outpatient secondary care) who have not been hos-
pitalized with HF for example, or vice versa.
Electronic health records (EHRs) are now used as an integral
part of routine daily practice in primary, and, to a lesser extent,
in secondary care in the UK.25,26 They provide an unprecedented
amount of data available for research and, as a result, have gained
increasing attention from the scientific community as well as gov-
ernmental institutions.27 Accordingly, we linked prospectively col-
lected data from primary care, hospital admissions, and death cer-
tificates for 2.1 million inhabitants of England in the Cardiovascu-
lar disease research using Linked Bespoke studies and Electronic
Health Records (CALIBER) programme.28 This platform has been
extensively validated for cardiovascular research.29–32 Our objec-
tives were to assess the distribution and prognostic impact of HF
among patients with HF recorded in primary care (including outpa-
tient secondary care) (PC), acute hospital admissions, or both. For
these respective strata, we assessed patient characteristics, their
HF management, and their prognosis in terms of 90-day and 5-year
mortality.
Methods
Study design and data sources
We used a cohort study design, based on the CALIBER programme, as
described previously.28 Table S1 in the Supplementary material online
summarizes the STROBE33 and RECORD34 checklists for reporting
on observational research in routinely collected health data. Briefly, ..
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.. CALIBER (www.caliberresearch.org) consists of linkage of four differ-
ent prospectively collected national data sources: the Clinical Prac-
tice Research Datalink (CPRD), the Myocardial Ischaemia National
Audit Project (MINAP) registry, Hospital Episodes Statistics (HES), and
cause-specific mortality in the Office for National Statistics (ONS).
CPRD is a research database containing anonymized electronic PC
records from 11.3 million patients in 674 general practitioner (GP)
practices throughout the UK (www.cprd.com).35 We used data from
2.13 million patients across 225 CPRD practices in England that con-
sented to data linkage.28 Previous work has shown that CPRD patients
are representative of the general population of the UK in terms of sex,
age, ethnicity,35,36 and overall mortality37, thereby validating CPRD for
epidemiological research.32 HES is a database containing dates and diag-
nostic codes for all elective and emergency admissions and procedures
to National Health Service hospitals in England (www.hscic.gov.uk/hes).
ONS is a database containing death certificates and provides date and
causes of death (www.ons.gov.uk/ons).
Study population and definition of heart
failure
We included all patients with incident HF from 1 January 1997 to 26
March 2010 (when all record sources were concurrent). The diagnosis
of HF was based on Read codes for CPRD data and International
Classification of Diseases (ICD)-9 or−10 codes in HES and ONS, using
a phenotyping approach previously described (details on algorithms
are available on www.caliberresearch.org/portal/ and Supplementary
material online, Table S2).38 We excluded patients under 30 years
of age and those not registered during the study period at a CPRD
practice, or whose CPRD practices did not submit data for at least
1 year before the diagnosis of HF. The study flow chart is shown in
the Supplementary material online, Figure S1. Based on the individual
distribution of HF records, we formulated four groups of interest based
on the presence or absence of a HF record in each of the three data
sources (Supplementary material online, Figure S2).
Clinical details of heart failure
We sought additional clinical details in the PC record relevant to
diagnosis and management, including LV dysfunction confirmed by
cardiac imaging, an elevated BNP concentration, referral to HF care,
referral to a cardiologist, the use of loop diuretics, and symptoms and
signs suggestive of HF. Relevant codes to support these criteria are
listed in Table S3 in the Supplementary material online.
Baseline characteristics
For each patient, information on demographics (i.e. age, sex, and
social deprivation), cardiovascular risk factors (i.e. smoking, hyperten-
sion, diabetes, systolic blood pressure, and body mass index), blood
tests (e.g. haemoglobin, creatinine, and BNP), co-existing morbidities
(COPD, cancer, and depression), and drug prescription [loop diuretics,
ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor
antagonists (MRAs)] were all obtained from PC consultations recorded
in CPRD. Risk factors and endpoints used in this study were previously
defined and their phenotyping algorithms combining Read, ICD-10,
drug, and procedure codes are published online and can be found
at http://www.caliberresearch.org/portal/.30,39 Measured values such as
blood pressure were based on the value closest to the first recorded
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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diagnosis date. A patient was considered to be adherent to a medica-
tion if there was at least one prescription of the drug present within
plus or minus 6 months of the HF diagnosis.
Statistical analyses
Hazard ratios (HRs) were derived from Cox models, with time since
first HF diagnosis as the time scale, adjusted for baseline age (lin-
ear), and stratified by sex and GP practice, to take clustering between
practices into account. Proportionality of hazard was verified by plot-
ting the Schoenfeld residuals. We produced Kaplan–Meier cumulative
incidence curves for 90-day and 5-year all-cause, cardiovascular, and
HF-specific mortality for HF patients, stratified by EHR source (Supple-
mentary material online, Figure S2). In Cox models of 5-year mortality,
we used the age- and sex-matched general population as the reference
group.Wematched patients with HF recorded in one of their EHRs in a
1:1 ratio with an age- and sex-matched general population drawn from
the 2.13 million study participants in CALIBER using the R package
‘MatchIt’ with caliper set at 0.15. Data were analysed using R version
3.1.2.
Ethical approval
This study was approved by the Independent Scientific Advisory
Committee of the Medicines and Healthcare products Regulatory
Agency (Protocol number 14_246R). The protocol was registered at
clinicaltrial.gov (NCT02551016).
Results
Distribution of heart failure in the
general population
Out of 2 134 615 patients in CALIBER, we identified 89 554
patients (4.2%) with a record of incident HF. The distribution of
HF recorded in primary care, hospital admissions, or cause of
death is shown in Figure 1. Out of all HF patients, 26% were
recorded in primary care only, 27% in both primary care and
hospital admissions, 34% in hospital admissions only, and 13%
had HF as cause of death without a previous record in primary
care or hospital admissions (Figure 1). Among patients with both
HF recorded in primary care and hospital admissions, 38% were
first recorded during hospitalization and the median time for
an accompanying record of HF in PC was 29 days [interquar-
tile range (IQR) 10–190 days] (Supplementary material online,
Figure S3). Lastly, 32 338 out of 54 310 (59.5%) patients who
were hospitalized for HF had a single HF-related hospitalization
episode throughout follow-up (Supplementary material online,
Figure S4)
Lifestyle, cardiovascular risk factors,
and co-morbidities
Patient characteristics, stratified by EHR source, are shown in
Table 1 and Supplementary material online Table S4. The median
age at diagnosis for patients known in PC but not hospitalized,
only hospitalized but not known in PC, or known in both levels ..
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Figure 1 Venn diagram showing the number and percentage of
records in primary care (CPRD), hospital admissions (HES), and
mortality registry (ONS) for heart failure across three national
sources in England, UK (n= 89 554).
of care was 78.8 years (IQR 70.9–85.6 years), 80.4 years (IQR
71.4–85.6 years), and 79.8 years (IQR 72.8–85.9), respectively,
with roughly similar percentages of female patients present in
the three respective groups (Table 1). Overall, cardiovascular risk
factors and co-morbidities were less common in patients with HF in
PC who were never hospitalized, and the highest prevalence was
observed in patients identified in HF-related hospital admissions
alone or in combination with PC, as were modifiable lifestyle
factors such as smoking (Table 1). Missing data are listed in the
Supplementary material online, Table S5. With regard to aetiology,
HF was recorded as ‘not otherwise specified’ in CPRD in 99.8%
(47 163 out of 47 228) of patients. However, the prevalence of
ischaemic heart disease, which can serve as a proxy for ischaemic
HF, was lowest in patients seen in PC but not hospitalized for
HF [10 332 out of 23 547 (43.9%) patients], compared with 15
346 out of 30 629 (50.1%) patients acutely hospitalized without
a PC record, or 13 421 out of 23 681 (56.7%) patients seen
in both levels of care (Table 1, P< 0.0001). Lastly, we found
that 60 042 (67.0%) patients had at least one item of additional
information of which a loop diuretic prescription and signs and
symptoms were most common (Supplementary material online,
Table S6).
Heart failure management
An ACE inhibitor or an ARB was prescribed in 13 138 out of
23 547 (55.8%) PC patients who were never hospitalized but only in
11 844 out of 30 629 (38.7%) patients hospitalized for HF without a
PC record, compared with the highest prescription rate in 17 057
out of 23 681 (72.0%) of patients known in both levels of care
(Table 1). In addition, beta-blockers were only prescribed in 7179
(30.5%), 7985 (26.1%), and 8190 (34.6%) of patients for these
three groups, respectively. The relatively newest evidence-based
treatment of HF is the addition of an MRA, and these were
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Characteristics of patients at time of heart failure recorded in primary care, hospital admissions, or both
(n= 77 857 patients)
CPRD CPRD and HES HES
Primary care record of HF but
never hospitalized for HF
Primary care record of HF and
hospitalized at least once for HF
Hospitalized for HF without
primary care record of HF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No. of patients 23 547 23 681 30 629
Patient characteristics
Median age (IQR) in years 78.8 (70.9–85.6) 79.8 (72.8–85.9) 80.4 (71.4–86.9)
Women (%) 12 098 (51.3%) 11 780 (49.7%) 16 005 (52.2%)
Most deprived fiftha 4806 (20.4%) 4312 (18.2%) 5976 (19.5%)
Current smokingb 2956 (14.1%) 3283 (14.9%) 5117 (19.3)
Ex-smokerb 6842 (32.6%) 7339 (33.5%) 7911 (29.9%)
Never smokedb 11 157 (53.3%) 11 272 (51.4%) 13 425 (50.8%)
Body mass index in kg/m2,b
mean± SD
27.1± 5.7 27.3± 5.9 27.0± 5.9
Systolic blood pressure in
mmHgb, mean± SD
142± 23 140± 24 139± 22
Serum creatinine, μmol/Lb 109± 86 117± 56 113± 68
Haemoglobin, mmol/Lb 13.2±1.9 12.8±1.9 12.8± 2.0
Co-morbidity
Hypertensionc 17 626 (74.9%) 19 881 (84.0%) 24 600 (80.3%)
Diabetes mellitusc 2095 (8.9%) 3898 (16.4%) 5493 (17.9%)
Atrial fibrillationc 6491 (27.6%) 10 793 (45.6%) 12 432 (40.6%)
Ischaemic heart diseasec 10 332 (43.9%) 13 421 (56.7%) 15 346 (50.1%)
Myocardial infarctionc 4959 (21.1%) 7503 (31.7%) 8863 (28.9%)
Strokec 663 (2.8%) 1047 (4.4%) 1962 (6.4%)
COPDc 4130 (17.5%) 5444 (23.0%) 6437 (21.0%)
Depressionc 4854 (20.6%) 4623 (19.5%) 6383 (20.8%)
Cancerc 4616 (19.6%) 4569 (19.3%) 7156 (23.4%)
Heart failure medication
Loop diureticsd 16 513 (70.1%) 20 911 (88.3%) 13 643 (44.5%)
ACE inhibitors/ARBd 13 138 (55.8%) 17 057 (72.0%) 11 844 (38.7%)
Beta-blockersd 7179 (30.5%) 8190 (34.6%) 7985 (26.1%)
HF beta-blockerse 3003 (12.8%) 5247 (22.2%) 3753 (12.3%)
MRAsd 2273 (9.7%) 5502 (23.2%) 2389 (7.8%)
CPRD, Clinical Practice Research Datalink; HES, Hospital Episodes Statistics; HF, heart failure; IQR, interquartile range; MRA, mineralocorticoid receptor antagonist;
SD, standard deviation.
aAssessed by index of multiple deprivation.
bMeasurement closest to and within 6 months before or on the date of HF diagnosis.
cPrior medical history of the given co-morbidity.
dDenotes present or prescribed± 6months of index date for HF diagnosis.
eHF beta-blockers include metoprolol, carvedilol, or bisoprolol.
prescribed in 2273 (9.7%) patients in the group known in PC
but not acute hospitalization, in 2389 (7.8%) patients acutely
hospitalized but not known in PC, compared with 5502 (23.2%)
patients known in both contexts.
Survival
We analysed 51 903 deaths over 206 055 person-years follow-up
[median follow up 1.7 years (IQR 0.22–4.43)]. Out of those, 17 230
(33.1%) occurred within 3 months, and descriptive characteristics
of patients dying within 3 months are listed in the Supplemen-
tary material online, Table S7. Figure 2 shows the Kaplan–Meier
curves for 90-day survival (Figure 2A–C), and 5-year survival in .
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.. patients who survived the first 3 months following diagnosis
(Figure 2D–F). The crude 5-year survival estimates for the above
strata were 21.7% [95% confidence interval (CI) 21.1–22.2%],
43.9% (95% CI 43.2–44.6%), and 39.8% (95% CI 39.2–40.5%),
respectively, compared with 88.1% (95% CI 87.9–88.3%) in the
age- and sex-matched general population (Table 2). Of note, all
three groups had slightly lower survival in women than in men
(Table 2). Corrected for age and sex, HF was strongly associated
with mortality, with HRs for all-cause mortality ranging from
7.01 (95% CI 6.83–7.20), 7.23 (95% CI 7.03–7.43), up to 15.38
(95% CI 15.02–15.83) for patients in primary care with acute HF
hospitalization, primary care only, and patients hospitalized but
no PC record, compared with the age- and sex-matched general
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Kaplan–Meier survival curves showing the survival following heart failure (HF) recorded in primary care, acute hospital admissions,
or both, for all-cause mortality (A and D), cardiovascular mortality (B and E), and HF as cause of death (C and F). (A–C) Ninety-day mortality;
(D–F) 5-year mortality in patients surviving the first 3 months. PC, primary care.
population (whose hazard was set as the reference) (Figure 3).
With regard to risk factors associated with poor outcome,
multivariable Cox proportional hazard models showed that age,
concomitant COPD, and diabetes were amongst the strongest
predictors of death (Supplementary material online, Table S8). .
..
..
..
..
..
..
.. Discussion
We assessed EHR data of >2 million people for the presence of
HF, within its real-world context using three linked data sources:
primary care (CPRD), hospital admissions for HF (HES), and the
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Five-year survival estimates with 95% confidence intervals in patients with heart failure recorded in primary
care, hospital admissions, or both compared with the age- and sex-matched general population
Source of heart failure record (HF population)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
General population CPRD CPRD and HES HES
Age- and sex-matched
general population
Primary care record
but never hospitalized
for HF
Primary care record of
HF and hospitalized at
least once for HF
Hospitalized for HF
without primary care
record of HF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No. of patients 77 857 23 547 23 681 30 629
Age < 55 years 99.7% (99.5–99.8%) 81.7% (79.1–84.3%) 69.7% (65.8–73.9%) 56.9% (53.7–60.3%)
Age 55–75 years 96.5% (96.3–96.7%) 62.1% (60.9–63.4%) 56.0% (54.7–57.3%) 40.0% (38.6–41.3%)
Age > 75 years 75.4% (74.9–75.8%) 32.7% (31.8–33.6%) 32.4% (31.6–33.2%) 13.2% (12.7–13.8%)
Men 88.7% (88.4–89.0%) 44.2% (43.2–45.3%) 41.3% (40.3–42.3%) 24.5% (23.6–25.4%)
Women 87.5% (87.2–87.8%) 43.6% (42.6–44.6%) 38.4% (37.4–39.3%) 19.2% (18.5–20.0%)
Total 88.1% (87.9–88.3%) 43.9% (43.2–44.6%) 39.8% (39.2–40.5%) 21.7% (21.1–22.2%)
CPRD, Clinical Practice Research Datalink; HES, Hospital Episodes Statistics; HF, heart failure.
mortality registry (ONS). Among nearly 90 000 patients identified
with HF, a quarter of all HF is recorded in primary care and these
patients are never hospitalized for HF—such patients are largely
excluded from trials, registries, and other studies—yet still had a
high 5-year mortality. Secondly, about a third of patients were given
their first diagnosis of HF during an acute hospitalization but were
not followed up after discharge in primary care. These patients
had the worst 5-year survival, and the worst medical management.
Taken together, these findings support the wider use of linked EHR
sources to facilitate a more consistent approach to identification,
profiling, and treatment of HF patients in the real world to improve
adherence to evidence-based care and reduce mortality.
Heart failure in primary care without
heart failure-related hospital
admissions—the 26%
Importantly, we found that in the UK, approximately a quarter of
all patients with HF in the general population were seen in primary
care—and presumingly also in the outpatient secondary care
setting—but were never acutely hospitalized for the disease. This
is roughly similar to that reported in the only other investigation
of the distribution of HF across different care settings.6 To our
knowledge, this is the first study that assessed the prognostic
burden of HF based on level of care. Here, we show that although
acute hospitalizations for HF are well known for their negative
impact on prognosis,15,16,40 unexpectedly 5-year survival estimates
were roughly comparable between primary care patients who
had never been hospitalized for HF and those who had. As the
natural course of HF commonly includes periods of destabilizations
requiring a hospital admission, it is uncertain which factors other
than HF hospital admissions are responsible for the low survival in
these patients. Although under-recording of hospital admissions in
HES cannot be ruled out, patients in this group could also reflect
end-stage HF in which the decompensated patient was not referred .
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. to the hospital as part of end-of-life counselling by the GP, or that
these patients died because of competing risks.
Hospitalization for heart failure without
a primary care record—the 34%
We found that ∼40% of all HF diagnoses in the general population
were made as a result of an acute hospitalization. Importantly, our
study shows (as has been described for other diseases, such as
cancer41) that de novo hospital admissions were strongly associated
with mortality compared with diagnoses that are formulated in
primary care or in a hospital outpatient setting. While it is possible
that some of these cases may have been fulminant, with no
opportunity for diagnosis in the community, it is likely that in many
cases the diagnosis during an acute admission was late and already
associated with high levels of disease severity.
Besides disease severity, it stands to reason that at least part
of their poor prognosis could be explained by their medical
management, being the worst of all three groups with the lowest
coverage of ACE inhibitors or ARBs, beta-blockers, and MRAs
(Table 1). Hence, the lack of a primary care record in these patients
might be the result of a quality of care gap between primary and
secondary care. Indeed, the importance of improved transition
between hospital and ambulant settings was recently reinforced
by Al-Dumluji et al. showing that high quality discharge summaries
were associated with a reduced number of readmissions.42
Heart failure diagnosis at death—
the 13%
With linkage to the national mortality register, this study advances
previous reports from Sweden6 or Germany7 by quantifying
HF-specific mortality. Notably, we found that 13% of 89 554
patients allegedly died of HF but were not recorded as having had
HF prior to their death in primary care, nor were they admit-
ted to the hospital for HF (Supplementary material online, Table
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Cox proportional hazard models for association between electronic health record record for heart failure (HF) and 5-year all-cause,
cardiovascular, and HF-related mortality, stratified by HF recorded in primary care, acute HF hospital admissions, or both. CI, confidence
interval; HR, hazard ratio.
S4). Work to characterize these patients further showed that they
were on average older, more frequently women, had higher levels of
social deprivation, and showed fewer traditional cardiovascular risk
factors. Although diagnosing HF as cause of death can be difficult,
these findings suggest that there could be opportunities for improv-
ing screening, identification, and treatment of HF in these elderly
patients, thereby potentially preventing HF-attributable deaths.
Limitations
The HF diagnoses used in this study were based on Read and/or
ICD codes related to HF. In general, diagnoses recorded in CPRD
or HES are sufficiently robust to permit their use for research
purposes.37,43 However, one limitation concerns the inability to val-
idate a diagnosis of HF directly using a gold standard (i.e. confirm
HF cases by expert panel review of clinical notes and diagnos-
tic tests) as CALIBER data are anonymized to safeguard patient
privacy. As in previous studies,30–32,39,44,45 we first examined char-
acteristics of patients identified by our EHR-driven HF pheno-
type in terms of demographics, cardiovascular risk factors, and
co-morbidity. Overall, patient characteristics were similar to those
observed in traditional HF registries1 as well as in EHR cohorts
from other European countries,6,7 which provides indirect evi-
dence of the validity of the code lists used for the identification of .
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.. patients with HF. Secondly, due to limitations inherent to routinely
collected EHR data, low rates of medication use can be caused by
under-recording (i.e. prescriptions for HF medication not recorded
by the GP in CPRD), misclassification of HF (i.e. no HF medica-
tion since patients do not have HF), true under-treatment of HF
patients, or a combination of the three. Overall, the impact of the
above-mentioned limitations are that, given an uncertain number
of coding errors or misdiagnoses leading to false positives (i.e.
patients recorded as having had HF but do not have HF in real
life), our prognostic estimates might even be biased towards the
conservative side.
Clinical implications
Our findings have important clinical implications. First, the joint
care in both primary and secondary care was associated with
higher prescription rates of HF medication. This leaves two large
groups of patients who could be potentially undertreated in current
practice, being patients solely seen in ambulatory care (i.e. primary
care and outpatient secondary care) and patients with a discharge
diagnosis of HF in acute hospital admissions without a concurrent
PC record. Higher levels of social deprivation in these two groups
hint that certain HF patients are prone to suboptimal treatment
in daily clinical care. Secondly, our findings underline the need for
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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follow-up after a discharge diagnosis of HF that should include a
pro-active diagnostic work-up with joint effort in both PC and
outpatient secondary care. With increasing evidence from the
real world generated from programmes such as CALIBER or the
ARNO database by Maggioni and co-workers,46 novel high-risk
groups become apparent, and those described in this study are
currently not reflected as high-risk individuals in US or European
guidelines.47,48 Lastly, to date, almost all clinical trials have been
enrolling patients with HF who have been hospitalized at least
once. Here, we show that this choice impairs the generalizability
towards a quarter of all HF patients in the general population who
are never hospitalized. To increase external validity, we propose
that future trials follow the BNP inclusion criterion as used in
the PARADIGM-HF trial involving sacubitril/valsartan, rather than
include trial participants based on an acute HF-related hospital
admission.49,50
Conclusions
In the general population, one in four patients with newly diag-
nosed HF will not be hospitalized for HF within a median follow-up
of 1.7 years, yet they still have a dismal 5-year prognosis. Patients
admitted to hospital with HF but not known with HF in primary
care have the worst management and survival. Mitigating the prog-
nostic burden of HF requires greater consistency across primary
and secondary care in the identification, profiling, and treatment of
patients.
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Table S5. Missing data on risk factors and patient characteristics
in primary care for patients with heart failure recorded in primary
care, hospital admissions, or death registry sources from 1 January
1997 to 26 March 2010.
Table S6. Recording of information supportive of a diagnosis
in patients with heart failure recorded in primary care, hospital
admissions, or mortality registry sources (n= 89 554).
Table S7. Recording of heart failure treatment and supportive
information in primary care of patients with heart failure recorded
in primary care, hospital admissions, or mortality registry, stratified
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